IV and Perineural Dexmedetomidine Similarly Prolong the Duration of Analgesia after Interscalene Brachial Plexus Block
- 1 March 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 124 (3) , 683-695
Abstract
In 99 patients receiving interscalene block with 15 ml ropivacaine, 0.5%, with 0.5 μg/kg dexmedetomidine prolonged the blockade and reduced the 24-h opioid use compared with placebo control, and these effects were similar whether dexmedetomidine was administered intravenously or perineurally. Background: Perineural and IV dexmedetomidine have each been suggested to prolong the duration of analgesia when administered in conjunction with peripheral nerve blocks. In the first randomized, triple-masked, placebo-controlled trial to date, the authors aimed to define and compare the efficacy of perineural and IV dexmedetomidine in prolonging the analgesic duration of single-injection interscalene brachial plexus block (ISB) for outpatient shoulder surgery. Methods: Ninety-nine patients were randomized to receive ISB using 15 ml ropivacaine, 0.5%, with 0.5 μg/kg dexmedetomidine administered perineurally (DexP group), intravenously (DexIV group), or none (control group). The authors sequentially tested the joint hypothesis that dexmedetomidine prolongs the duration of analgesia and reduces the 24-h cumulative postoperative morphine consumption. Motor blockade, pain severity, hemodynamic variations, opioid-related side effects, postoperative neurologic symptoms, and patient satisfaction were also evaluated. Results: Ninety-nine patients were analyzed. The duration of analgesia was 10.9 h (10.0 to 11.8 h) and 9.8 h (9.0 to 10.6 h) for the DexP and DexIV groups, respectively, compared with 6.7 h (5.6 to 7.8) for the control group (P < 0.001). Dexmedetomidine also reduced the 24-h cumulative morphine consumption to 63.9 mg (58.8 to 69.0 mg) and 66.2 mg (60.6 to 71.8 mg) for the DexP and DexIV groups, respectively, compared with 81.9 mg (75.0 to 88.9 mg) for the control group (P < 0.001). DexIV was noninferior to DexP for these outcomes. Both dexmedetomidine routes reduced the pain and opioid consumption up to 8 h postoperatively and did not prolong the duration of motor blockade. Conclusion: Both perineural and IV dexmedetomidine can effectively prolong the ISB analgesic duration and reduce the opioid consumption without prolonging motor blockade.Keywords
This publication has 69 references indexed in Scilit:
- Is intraoperative dexmedetomidine a new option for postoperative pain treatment? A meta-analysis of randomized controlled trialsPain, 2013
- Perineural Dexmedetomidine Added to Ropivacaine for Sciatic Nerve Block in Rats Prolongs the Duration of Analgesia by Blocking the Hyperpolarization-activated Cation CurrentAnesthesiology, 2011
- Preventive analgesiaCurrent Opinion in Anaesthesiology, 2011
- Neurotoxicity of Adjuvants Used in Perineural Anesthesia and Analgesia in Comparison With RopivacaineRegional Anesthesia & Pain Medicine, 2011
- Transient Heat Hyperalgesia During Resolution of Ropivacaine Sciatic Nerve Block in the RatRegional Anesthesia & Pain Medicine, 2011
- Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node MetastasisJAMA, 2011
- Perineural Dexmedetomidine Added to Ropivacaine Causes a Dose-dependent Increase in the Duration of Thermal Antinociception in Sciatic Nerve Block in RatAnesthesiology, 2009
- A Surgical Safety Checklist to Reduce Morbidity and Mortality in a Global PopulationNew England Journal of Medicine, 2009
- Effect of dexmedetomidine on the characteristics of bupivacaine in a caudal block in pediatricsActa Anaesthesiologica Scandinavica, 2009
- Perineural Administration of Dexmedetomidine in Combination with Bupivacaine Enhances Sensory and Motor Blockade in Sciatic Nerve Block without Inducing Neurotoxicity in RatAnesthesiology, 2008